Johnson & Johnson (JNJ) Holdings Boosted by Family Firm Inc.

Family Firm Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 13.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,318 shares of the company’s stock after buying an additional 627 shares during the period. Family Firm Inc.’s holdings in Johnson & Johnson were worth $703,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Pachira Investments Inc. lifted its position in shares of Johnson & Johnson by 12.2% during the first quarter. Pachira Investments Inc. now owns 4,424 shares of the company’s stock worth $551,000 after purchasing an additional 480 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI lifted its position in shares of Johnson & Johnson by 0.5% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 114,681 shares of the company’s stock worth $14,283,000 after purchasing an additional 544 shares in the last quarter. Cedar Wealth Management LLC lifted its position in shares of Johnson & Johnson by 5.3% during the first quarter. Cedar Wealth Management LLC now owns 3,294 shares of the company’s stock worth $410,000 after purchasing an additional 167 shares in the last quarter. Usca Ria LLC lifted its position in shares of Johnson & Johnson by 4.7% during the first quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,244 shares in the last quarter. Finally, Willingdon Wealth Management lifted its position in shares of Johnson & Johnson by 11.8% during the first quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock worth $1,614,000 after purchasing an additional 1,372 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) traded down $0.97 during trading hours on Tuesday, reaching $139.01. 5,916,600 shares of the company’s stock traded hands, compared to its average volume of 5,873,962. Johnson & Johnson has a 1 year low of $109.32 and a 1 year high of $144.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The company has a market capitalization of $376,059.06, a P/E ratio of 19.60, a PEG ratio of 2.85 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the prior year, the firm earned $1.68 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. equities analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.42%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s payout ratio is presently 58.33%.

JNJ has been the topic of a number of research reports. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Citigroup initiated coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price target for the company. Goldman Sachs Group downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Finally, Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $144.59.

TRADEMARK VIOLATION NOTICE: This article was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/05/johnson-johnson-jnj-holdings-boosted-by-family-firm-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply